title: Overcoming obstacles to repurposing for neurodegenerative disease.
abstract: Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.
authors.affiliation: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
authors.forename: Diana W
authors.initials: DW
authors.lastname: Shineman
authors.affiliation: Eip pharma, LLC 11 Channing Street, Cambridge, Massachusetts, 02183.
authors.forename: John
authors.initials: J
authors.lastname: Alam
authors.affiliation: Faster Cures 1101 New York Ave, NW Suite 620, Washington, District of Columbia, 20005.
authors.forename: Margaret
authors.initials: M
authors.lastname: Anderson
authors.affiliation: Sunnybrook Health Sciences Centre, University of Toronto Room A421- 2075, Bayview Avenue, Toronto, Ontario, M4N 3M5.
authors.forename: Sandra E
authors.initials: SE
authors.lastname: Black
authors.affiliation: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Carman
authors.affiliation: Cleveland Clinic 888 W Bonneville Ave, Las Vegas, Nevada, 89106.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Cummings
authors.affiliation: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
authors.forename: Penny A
authors.initials: PA
authors.lastname: Dacks
authors.affiliation: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai One Gustave L Levy Pl, New York City, New York, 10029.
authors.forename: Joel T
authors.initials: JT
authors.lastname: Dudley
authors.affiliation: AstraZeneca 35 Gatehouse Drive, Waltham, Massachusetts, 02451.
authors.forename: Donald E
authors.initials: DE
authors.lastname: Frail
authors.affiliation: SDG, LLC One Mifflin Place, Suite 400, Cambridge, Massachusetts, 02138.
authors.forename: Allan
authors.initials: A
authors.lastname: Green
authors.affiliation: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
authors.forename: Rachel F
authors.initials: RF
authors.lastname: Lane
authors.affiliation: FaegreBD Consulting 1050 K Street NW, Suite 400, Washington, District of Columbia, 20001.
authors.forename: Debra
authors.initials: D
authors.lastname: Lappin
authors.affiliation: Northwestern University Feinberg School of Medicine 710 North Lake shore Drive, Chicago, Illinois, 60611.
authors.forename: Tanya
authors.initials: T
authors.lastname: Simuni
authors.affiliation: The Access Group 400 Connell Drive FL2, Berkeley Heights, New Jersey, 07922.
authors.forename: Richard G
authors.initials: RG
authors.lastname: Stefanacci
authors.affiliation: The Michael J. Fox Foundation for Parkinson's Research Grand Central Station, P.O. Box 4777, New York City, New York, 10163-4777.
authors.forename: Todd
authors.initials: T
authors.lastname: Sherer
authors.affiliation: Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
authors.forename: Howard M
authors.initials: HM
authors.lastname: Fillit